MPA
IBB icon

Marvin & Palmer Associates’s iShares Biotechnology ETF IBB Stock Holding History

Marvin & Palmer Associates’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,824
Closed -$3.68M – 33
2026
Q1 		$3.68M Sell
21,824
-20,395
-48% -$3.49M 4.41% 10
2025
Q4 		$7.13M Buy
+42,219
New +$6.86M 5.03% 7

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Marvin & Palmer Associates's IBB Position: Q2 2026 in Review

Marvin & Palmer Associates sold out of iShares Biotechnology ETF (IBB) in Q2 2026, closing a stake of 21,824 shares — an estimated $3.68M sold.

Marvin & Palmer Associates first reported a position in IBB in Q4 2025 and held it in 2 quarters. The position peaked at $7.13M in Q4 2025. 955 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Marvin & Palmer Associates reported no remaining iShares Biotechnology ETF position as of Q2 2026 after selling out during the quarter.
  • Marvin & Palmer Associates sold 21,824 iShares Biotechnology ETF shares in Q2 2026, an estimated $3.68M.
  • Marvin & Palmer Associates first reported a position in iShares Biotechnology ETF in Q4 2025 and held it in 2 quarters.
  • Marvin & Palmer Associates's iShares Biotechnology ETF position peaked at $7.13M in Q4 2025.
  • 955 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Marvin & Palmer Associates's 13F filing for Q2 2026, filed 7 Aug 2026.